SenzaGen invited to prestigious meeting at ICCVAM, US

On Tuesday the 27 September SenzaGen is invited to participate at a science Committee Meeting of the American organization ICCVAM *, which promotes the development of alternative methods to replace animal testing. Together with its US partner, Burleson Research Technologies, Inc., SenzaGen will participate in the official program and make a statement about Skin Sensitization Testing, the importance of secure and robust tests for classification of chemical substances with the ability to identify the potential of a substance causing allergy.

US ICCVAM is a permanent committee consisting of representatives from 15 federal regulatory and research agencies that requires, uses, generates, or disseminates toxicological and safety testing information to replace animal experiments. ICCVAM take expert advice from SACATM **, whose members include stakeholders from regulated industries, animal welfare organizations, academia, U.S. state or international regulatory bodies, and companies or organizations that develop, market or use test methods.

In connection with the SACATM meeting SenzaGen was invited together with their partner Burleson Research Technologies to make a statement in the session for Skin Sensitization Testing.

– It is a great achievement for us that we now have the opportunity, together with our partner Burleson Research Technologies, to give our views on the future development of testing in the U.S and to present GARD, before members of the prestigious SACATM. This shows that GARD is already on their radar, as the next-generation of sensitization testing. Only by cooperating at the highest level can we set a new industry standard for allergy testing in the US market, says Anki Malmborg Hager, CEO of SenzaGen.

The ICCVAM meeting is being held in Research Triangle Park, North Carolina on Tuesday, 27 September and the CEO of SenzaGen AB, Anki Malmborg Hager will make her statement and give the recommendations in the session ICCVAM Roadmap to Skin Sensitization Testing at 11.25 am (EDT).

* ICCVAM: The Interagency Coordinating Committee on the Validation of Alternative Methods
** SACATM: Scientific Advisory Committee on Alternative Toxicological Methods

 

For more information:

Anki Malmborg Hager, CEO, SenzaGen AB
E-mail: amh@senzagen.com
Phone: +46 768 284822

Brian Rogers, CEO US
E-mail: brian.rogers@senzagen.com
Phone: +1 530 304 7648, +1 530 867 5600